---
title: "CSPC PHARMA, AstraZeneca Forge Collaboration, Option and License Agreement for Development of siRNA Drugs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291519971.md"
description: "CSPC PHARMA and AstraZeneca signed a collaboration, option, and license agreement to develop siRNA drugs. They will jointly discover preclinical candidates for renal diseases using CSPC's platforms. AstraZeneca holds global or non-China exclusive rights options, while CSPC retains China rights for one candidate."
datetime: "2026-07-02T08:50:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291519971.md)
  - [en](https://longbridge.com/en/news/291519971.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291519971.md)
generator: "portal-rs"
---

# CSPC PHARMA, AstraZeneca Forge Collaboration, Option and License Agreement for Development of siRNA Drugs

CSPC PHARMA (01093.HK) +0.580 (+8.321%) Short selling $356.82M; Ratio 27.493% announced that it entered into a collaboration, option and license agreement with AstraZeneca (AZN.US) to establish a strategic research collaboration and utilise the Group’s proprietary siRNA drug discovery platform and extrahepatic targeted delivery platform to develop novel small nucleic acid drug candidates.

Under the terms of the Agreement, the Group and AstraZeneca will jointly discover and develop preclinical candidates (PCC) for two targets, with the potential to treat renal diseases across multiple indications. For each PCC program, AstraZeneca will have the option to obtain the exclusive rights for the development, manufacturing and commercialisation globally or outside of China (as applicable). The Group will retain the rights to develop, manufacture and commercialise one of the PCCs in China.  
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-02 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

### Related Stocks

- [300765.CN](https://longbridge.com/en/quote/300765.CN.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [Cramer's lightning round: 'I am not going to put my money on AstraZeneca'](https://longbridge.com/en/news/298373941.md)
- [AstraZeneca publishes transcript of ERS 2026 investor call and webcast](https://longbridge.com/en/news/298346504.md)
- [Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials](https://longbridge.com/en/news/298355260.md)
- [AstraZeneca Announces Approval Of Etcamah Combination In The US](https://longbridge.com/en/news/298174661.md)
- [RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)](https://longbridge.com/en/news/298372812.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**